Comparative Study of New Drug Approval Processes in India, US and Canada

Read full text Summarise with VIRAT
Authors: Pranali Arun Pawar, Aneri.V.Adsul, Prajakta Arun Pawar
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ABSTRACT A regulatory process of drug approval is very important in ensuring that new pharmaceutical products are safe, effective and produced without quality standards. In this review, the approval procedures in India, The US and Canada are compared. This also involves an organized evaluation that is supported by scientists. The three systems aim to safeguard the well-being of the masses by ensuring that medicines reach the patients only when they are well characterized, evidence based, and of the highest quality, irrespective of the system structure, documentation requirements, reviewing period and the regulatory authority roles. This comparative study outlines similarities and specific regulatory aspects to define Indian, U.S., and Canadian drug-approval process. Keywords: Drug approval process, Regulatory affairs, Pharmaceutical regulations, New drug approval, CDSCO, USFDA, Health Canada, Clinical trials, Regulatory authority, Drug safety and efficacy.

Fields of Study & Subjects

Healthcare Regulation Pharmaceutical Economics and Policy Biomedical Ethics and Regulation

Publication details

Journal / source
American Journal Of Pharmacy And Health Research
Publication date
25 February 2026
Language
EN